Business
Aligos Therapeutics to Present Data from Chronic Hepatitis B and Hepatocellular Carcinoma Programs at the European Association for the Study of the Liver (EASL) Congress 2023
SOUTH SAN FRANCISCO, Calif., April 11, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused
About this update from Aligos Therapeutics, Inc.
[{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., April 11, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that the company will present seven posters collectively highlighting data out of five of its liver disease programs at the European Association for the Study of the Liver (EASL) Congress 2023, taking place in Vienna, Austria, June 21 – 24, 2023. The presentations will be available on the Scientific Presentations and Conferences page on Aligos’ corporate website following the meeting. “We are pleased to present seven abstracts at this year’s EASL meeting,” said Lawrence Blatt, Ph.D., MBA, Chairman & CEO of Aligos Therapeutics. “We believe these programs demonstrate the potential to serve as best-in-class compounds with significant value to patients and shareholders. We look forward to sharing additional detail at the time of the conference and further results throughout the year.” Poster presentation details are below. Chronic hepatitis B CAM-E ALG-000184Abstract title: Treatment for up to 24 weeks with the capsid assembly modulator ALG-000184 results in dose related reductions in HBsAg in subjects with HBeAg positive chronic hepatitis BPresenter: Jinlin Hou, M.D. siRNA ALG-125755Abstract title: Safety, pharmacokinetics, and antiviral activity of single ascending doses of ALG-125755, a GalNAc-conjugated small interfering RNA, in subjects with chronic hepatitis BPresenter: Alina Jucov, M.D., Ph.D. Abstract title: Pharmacodynamic durability of ALG-125755, a GalNAc-conjugated siRNA, correlated with total and RNA induced complex (RISC) bound siRNA in mouse liverPresenter: Kusum Gupta Small molecule PD-L1 inhibitor ALG-093702Abstract title: Preclinical pharmacokinetic, pharmacodynamic and efficacy relationships of ALG-093702, a liver targeted PD-L1 small molecule inhibitor, in different in vivo modelsPresenter: Tongfei Wu, Ph.D. siRNA PD-L1 inhibitor Abstract title: A potent human PD-L1 siRNA leads to significant reduction of AAV-HBV infected hepatocytes via immune activation in human PD-1/PD-L1 double knock in micePresenter: Jin Hong, Ph.D. Hepatitis B virus model systemAbstract title: An in vivo duck hepatitis B virus model recapitulates key aspects of nucleic acid polym...